Zobrazit více v PubMed
Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases. Am J Med Sci. 1893;10:487–511. doi: 10.1097/00000441-189305000-00001.
PubMed
DOI
Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med. 2007;13:552–9. doi: 10.1038/nm1589.
PubMed
DOI
Guha M. Anticancer TLR, agonists on the ropes. Nat Rev Drug Discov. 2012;11:503–5. doi: 10.1038/nrd3775.
PubMed
DOI
Janotová T, Jalovecká M, Auerová M, Švecová I, Bruzlová P, Maierová V, et al. The use of anchored agonists of phagocytic receptors for cancer immunotherapy: B16-F10 murine melanoma model. PLoS One. 2014;9(1):e85222. doi: 10.1371/journal.pone.0085222.
PubMed
DOI
PMC
Waldmannová E, Caisová V, Fáberová J, Sváčková P, Kovářová M, Sváčková D, et al. The use of Zymosan A and bacteria anchored to tumor cells for effective cancer immunotherapy: B16-F10 murine melanoma model. Int Immunopharmacol. 2016;39:295–306. doi: 10.1016/j.intimp.2016.08.004.
PubMed
DOI
Warren TS, Fitting C, Hoff E, Adib-Conquy M, Beasley-Topliffe L, Tesini B, et al. Resilience to bacterial infection: difference between species could be due to proteins in serum. J Infect Dis. 2010;201:223–32. doi: 10.1086/649557.
PubMed
DOI
PMC
Yamamoto Y, Harashima A, Saito H, Tsuneyama K, Munesue S, Motoyoshi S, et al. Septic shock is associated with receptor for advanced glycation end products ligation of LPS. J Immunol. 2011;186(5):3248–57. doi: 10.4049/jimmunol.1002253.
PubMed
DOI
Torosantucci A, Bromuro C, Chiani P, De Bernardis F, Berti F, Galli C, et al. A novel glyco-conjugate valine against fungal pathogens. JEM. 2005;202:597–606. doi: 10.1084/jem.20050749.
PubMed
DOI
PMC
Kato K, Itoh C, Yasukouchi T, Nagamune T. Rapid protein anchoring into the membranes of mammalian cells using oleyl chain and poly(etylene glycol) derivatives. Biotechnol Prog. 2004;20:897–904. doi: 10.1021/bp0342093.
PubMed
DOI
Christiaansen JF, Gallardo D, Burnside SS, Nelson AA, Sears DW. Rapid covalent coupling of proteins to cell surfaces: Immunological characterization of viable protein-cell conjugates. J Immunol Methods. 1984;74:229–39. doi: 10.1016/0022-1759(84)90290-4.
PubMed
DOI
Li J, Piao YF, Jiang Z, Chen L, Sun HB. Silencing of signal transducer and activator of transcription 3 expression by RNA interference suppresses growth of human hepatocellular carcinoma in tumor-bearing nude mice. World J Gastroenterol. 2009;15:2602–8. doi: 10.3748/wjg.15.2602.
PubMed
DOI
PMC
Stassen M, Valeva A, Walev I, Schmitt E. Activation of mast cells by streptolysin O and lipopolysaccharide. Methods Mol Biol. 2006;315:393–403.
PubMed
Dewas C, Dang PM, Gougerot-Pocidalo MA, El-Benna J. TNF-alpha induces phosphorylation of p47phox in human neutrophils: Partial phosphorylation of p47phox is a common event of priming of human neutrophils by TNF-alpha and granulocyte-macrophage colony-stimulating factor. J Immunol. 2003;171:4392–8. doi: 10.4049/jimmunol.171.8.4392.
PubMed
DOI
Wright HL, Moots RJ, Bucknall RC, Edwards SW. Neutrophil function in inflammation and inflammatory diseases. Rheumatology. 2010;49:1618–31. doi: 10.1093/rheumatology/keq045.
PubMed
DOI
Takayama K, Ribi E, Cantrell JL. Isolation of a nontoxic lipid A fraction containing tumor regression activity. Cancer Res. 1981;41:2654–7.
PubMed
Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosporyl lipid A as a TRIF-biased agonist of TLR4. Science. 2007;316(5831):1628–32. doi: 10.1126/science.1138963.
PubMed
DOI
Smits EL, Ponsaerts P, Berneman ZN, Van Tendeloo VF. The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist. 2008;13(8):859–75. doi: 10.1634/theoncologist.2008-0097.
PubMed
DOI
Schőn MP, Schőn M. TLR7 and TLR8 as targets in cancer therapy. Oncogene. 2008;27:190–9. doi: 10.1038/sj.onc.1210913.
PubMed
DOI
Bourquin C, Hotz C, Noerenberg D, Voelkl A, Heidegger S, Roetzer LC, et al. Systemic cancer therapy with a small molecule agonist of Toll-like receptor 7 can be improved by circumventing TLR tolerance. Cancer Res. 2011;71(15):5123–33. doi: 10.1158/0008-5472.CAN-10-3903.
PubMed
DOI
Sato S, Takeuchi O, Fujito T, Tomizawa H, Takeda K, Akira S. A variety of microbial components induce tolerance to lipopolysaccharide by differentially affecting MyD88-dependent and -independent pathways. Int Immunol. 2002;14:783–91. doi: 10.1093/intimm/dxf046.
PubMed
DOI
Tsukada K, Kitazawa T, Fukushima A, Okugawa S, Yanagimoto S, Tatsuno K, et al. Macrophage tolerance induced by stimulation with Toll-like receptor 7/8 ligands. Immunol Lett. 2007;111:51–6. doi: 10.1016/j.imlet.2007.05.001.
PubMed
DOI
Chan T, Wiltrout RH, Weiss JM. Immunotherapeutic modulation of the suppressive liver and tumor microenvironments. Int Immunopharmacol. 2011;11(7):879–89. doi: 10.1016/j.intimp.2010.12.024.
PubMed
DOI
PMC
Lee M, Park CS, Lee YR, Im SA, Song S, Lee CK. Resiquimod, a TLR7/8 agonist, promotes differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells. Arch Pharm Res. 2014;37(9):1234–40. doi: 10.1007/s12272-014-0379-4.
PubMed
DOI
Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood. 2003;102:2660–9. doi: 10.1182/blood-2003-04-1078.
PubMed
DOI
Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002;218:74–86. doi: 10.1016/S0008-8749(02)00517-8.
PubMed
DOI
Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol. 2000;203:55–65. doi: 10.1006/cimm.2000.1673.
PubMed
DOI
Zhang WW, Matlashewski G. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun. 2008;76:3777–83. doi: 10.1128/IAI.01527-07.
PubMed
DOI
PMC
Zagon IS, Donahue RN, Rogosnitzky M, McLaughlin PJ. Imiquimod upregulates the opioid growth factor receptor to inhibit cell proliferation independent of immune function. Exp Biol Med. 2008;233(8):968–79. doi: 10.3181/0802-RM-58.
PubMed
DOI
Yeung VP, Gieni RS, Umetsu DT, DeKruyff RH. Heat-killed Listeria monocytogenes as an adjuvant converts established murine Th2-dominated immune responses into Th1-dominated responses. J Immunol. 1998;161:4146–52.
PubMed
Trinchieri G, Sher A. Cooperation of toll-like receptor signals in innate immune defence. Nat Rev Immunol. 2007;7:179–90. doi: 10.1038/nri2038.
PubMed
DOI
Tan RST, Lin B, Liu Q, Tucker-Kellogg LT, Ho B, Leung BPL, Ding JL. The synergy in cytosine production through MyD88-TRIF pathways is co-ordinated with ERK phosphorylation in macrophages. Immunol Cell Biol. 2013;91:377–87. doi: 10.1038/icb.2012.54.
PubMed
DOI
Verdijk RM, Mutis T, Esendam B, Kamp J, Melief CJM, Brand A, Goulmy E. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J Immunol. 1999;163:57–61.
PubMed
Tsujimoto H, Efron PA, Matsumoto T, Ungatro RF, Abouhamze A, Ono S, et al. Maturation of murine bone marrow-derived dendritic cells with poly(I:C) produces altered TLR-9 expression and response to CpG DNA. Immunol Lett. 2006;107:155–62. doi: 10.1016/j.imlet.2006.09.001.
PubMed
DOI
Wald M, Olejar T, Sebkova V, Zadinova M, Boubelik M, Pouckova P, Suppl Mixture of trypsin, chymotrypsin and papain reduces formation of metastases and extends survival time of C57Bl6 mice with syngeneic melanoma B16. Cancer Chemother Pharmacol. 2001;47:16–22. doi: 10.1007/s002800170004.
PubMed
DOI